Wearability of and Myopia Progression With ZEISS MyoCare Spectacle Lenses

Launched by ZEISS VISION CARE · Jun 13, 2025

Keywords

ClinConnect Summary

The clinical trial titled "Wearability of and Myopia Progression With ZEISS MyoCare Spectacle Lenses" is studying how well different types of ZEISS glasses can help manage myopia, commonly known as nearsightedness, in children. The trial will compare three types of ZEISS lenses over six months to see which ones are most comfortable to wear and how effective they are in slowing down myopia progression. To participate, children aged 7 to 13 with specific levels of myopia and normal eye health are eligible, provided they have a parent or guardian who can read and understand English or Vietnamese.

Participants in the trial will be randomly assigned to wear one of the three types of lenses and will need to visit the eye clinic five times over six months, along with two virtual check-ins at home. This study is currently recruiting participants, and it’s important for parents to know that children with certain eye conditions or health issues may not be eligible. Overall, this trial aims to find better ways to help manage myopia in children, which could lead to healthier vision in the future.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • be accompanied by a parent or guardian who is able to read and comprehend Vietnamese/English and sign a record of informed consent/assent;
• • at baseline, be within the age range of 7 to 13 years old inclusive;
• • be diagnosed as myopic having cycloplegic spherical equivalent between -0.75 dioptre (D) and -5.00 dioptre (D);
• • astigmatism ≤1.50D;
• • anisometropia of not more than 1.50D;
• • be willing to comply with the wearing of clinical trial spectacles and clinical trial visit schedule as directed by the investigator;
• • have ocular findings deemed to be normal;
• • vision correctable to at least 0.8 or better in each eye with spectacles.
• Exclusion Criteria:
• • Any pre-existing systemic or ocular condition, including infection or disease that is likely to affect visual acuity and refractive error;
• • Any systemic disease that adversely affects ocular health e.g. diabetes, Graves disease, and auto-immune diseases such as ankylosing spondylitis, multiple sclerosis, Sjögrens syndrome and systemic lupus erythematosus.
• • Use of or a need for any systemic medication or topical medications which may alter normal ocular findings / are known to affect a participant's ocular health / physiology in an adverse or beneficial manner at enrolment and/or during the clinical trial. NB: Systemic antihistamines are allowed on an "as needed basis", provided they are not used prophylactically during the trial and at least 24 hours before the clinical trial product is used.
• • History of eye trauma or eye surgery
• • Amblyopia
• • Anisometropia of not more than 1.50D
• • Strabismus
• • History of use of myopia control interventions such as Orthokeratology or atropine 3 months prior to commencement of this trial.
• • Known allergy or intolerance to ingredients to cycloplegic eye-drops.
• • Currently enrolled in another clinical trial.